Efficacy of tirofiban combined with low-molecular-weight heparin in treatment of acute coronary syndrome
10.3760/cma.j.issn.0254-9026.2014.02.009
- VernacularTitle:替罗非班联合低分子肝素治疗急性冠状动脉综合征临床疗效观察
- Author:
Hongxia GONG
;
Xiaoliang CAO
;
Wenai CHEN
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Heparin,low-molecular-weight;
Platelet aggregation inhibitors
- From:
Chinese Journal of Geriatrics
2014;33(2):147-149
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of tirofiban combined with lowmolecular-weight heparin in treatment of acute coronary syndrome.Methods 138 patients with acute coronary syndrome were divided into two groups(observation group and control group).In observation group,80 cases were treated with tirofiban combined with low-molecular-weight heparin on the basis of conventional therapy.In control group,58 cases were treated with low-molecularweight heparin on the basis of conventional therapy.The efficacy and safety were compared between the two groups.Results The total efficacy was higher in observation group than in control group (x2=8.589,P＜ 0.01).The improvement of 24 h anginal attacks,decrease in values of ECG ST segment and cardiac troponin T value were better in observation group than in control group(all P＜ 0.05).The blood platelet count and adverse reactions were not different between the two groups(t=0.294,x2 =0.747,both P ＞ 0.05).Conclusions Tirofiban combined with low-molecular-weight heparin is effective and safe in the treatment of acute coronary syndrome.It can increase the clinical effect,improve clinical symptoms and signs in the patients,and is worthy of clinical application.
